Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SGN-30, a chimeric anti-CD30 MAb, in the treatment of Hodgkin's disease

April 23, 2002

Patient treatment begun in phase I/IIa trial of ZYC-300

April 18, 2002

Over 95% of prostate cancer patients express target of Provenge vaccine

April 16, 2002

Phase I/II results for WX-G250 in metastatic RCC indicate clinical benefit and good tolerance

April 15, 2002

Long-term survival findings reported for Multikine in head and neck cancer

April 12, 2002

MVA-Muc1-IL-2 enters new phase II trial in prostate cancer

April 10, 2002

LifeTime acquires Beta LT

April 8, 2002

CpG-7909 in combination with Rituxan evaluated in non-Hodgkin's lymphoma

April 3, 2002

Seattle Genetics initiates phase I monoclonal antibody study

March 25, 2002

Results reported in Barcelona for DNA and protein AutoVac HER-2 vaccines

March 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
Quince’s eDSP on ice after Neat phase III fails in A-T
BioWorld
Quince Therapeutics Inc. is scrapping work with dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) for patients with...